- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00089284
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90-Yttrium- Zevalin and the Redox- Modulating Agent, Motexafin Gadolinium (MGd)
Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug.
This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase I, dose-escalation study of motexafin gadolinium followed by a phase II study. Patients are stratified according to extent of lymphomatous involvement (≤ 5% vs > 5 but ≤ 24% of cellular elements).
Cohorts of 3-6 patients in each stratum receive escalating doses of motexafin gadolinium until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity (DLT) OR the dose preceding that at which 2 of 3 or 3 of 6 patients experience DLT.
- Once the MTD is determined, additional patients are treated at that dose level as in phase I.
Patients are followed weekly for 3 months and then monthly for 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611-3013
- Northwestern University
-
Chicago, Illinois, United States, 60611
- Jesse B. Brown Veterans Affairs Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of one of the following:
Low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL)
The following histologies are eligible:
- Small lymphocytic lymphoma
- Lymphoplasmacytoid lymphoma
- Follicular center grades 1, 2, or 3 lymphoma
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type
- Nodal marginal zone B-cell lymphoma
- Relapsed or refractory after 2 prior treatment regimens or 1 anthracycline regimen
- Diffuse large B-cell NHL or mantle cell lymphoma in first or second relapse
- Transformed NHL, defined as low-grade NHL transformed to diffuse large B-cell lymphoma, with no more than 1 relapse since transformation
Age 18 and over Recovered from prior immunotherapy Life expectancy At least 3 months Recovered from prior chemotherapy
- More than 4 weeks since prior major surgery and recovered
- More than 4 weeks since prior anticancer therapy recovered from prior radiotherapy
Exclusion criteria:
No major bleeding within the past 4 weeks No uncontrolled hypertension No stroke within the past 4 weeks
- No active infection
- No other active nonmalignant disease
- No known G6PD deficiency
- No history of porphyria
- No other condition that would preclude study participation
- No human anti-mouse antibodies
- No known history of HIV
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior radioimmunoconjugate therapy
- No prior exposure to murine antibodies other than rituximab
- More than 4 weeks since prior rituximab
- No history of failed stem cell collection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituxan and 90Yttrium-Zevalin plus MGd
Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11.
At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8.
After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1.
Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7.
If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
|
Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11.
At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8.
After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1.
Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7.
If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Other Names:
Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11.
At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8.
After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1.
Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7.
If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Other Names:
Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11.
At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8.
After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1.
Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7.
If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicities (DLT)
Time Frame: Weekly during treatment and continuing up through Day 90
|
The number of Dose Limiting Toxicities (DLT) observed in patients treated with Motexafin Gadolinium at different dose levels in combination with Rituxan, Indium-Zevalin, and 90Yttrium-Zevalin was used to determine the Maximum Tolerated Dose (MTD) to be used for phase II of the study. The number of dose-limiting toxicities observed in each cohort of patients determined whether to continue dose escalation. Each cohort = at least 3 patients. All toxicities will be graded according to the NCI Common Toxicity Criteria, version 2.0, with a DLT defined as any of the following: Grade 3 or 4 non-hematologic toxicity (other than grade 3 nausea or vomiting). Grade 4 vomiting despite maximal antiemetic support. Grade 4 neutropenia and thrombocytopenia either lasting longer than 14 days-Grade 4 duration will be measured (in days) from the first date in grade 4 to last date in grade 4 after nadir (growth factor and transfusion independent, respectively). |
Weekly during treatment and continuing up through Day 90
|
Maximum Tolerated Dose (MTD)
Time Frame: Weekly during treatment and continuing up through Day 90
|
The maximum tolerated dose (MTD) of Motexafin Gadolinium in combination with Rituxan, Indium-Zevalin, and 90Yttrium-Zevalin was determined using a modified Fibonacci phase I study design (with patient allocation based on amount of lymphoma bone marrow involvement) and will be used in phase II of the study.
The MTD will be that dose at which 0/3 or 1/6 patients or 2/9 experience a Dose Limiting Toxicity (DLT), with the next higher dose level provoking DLT in 2/3 or 3/6 or 4/9 patients.
|
Weekly during treatment and continuing up through Day 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-lymphoma Efficacy
Time Frame: At 1, 3 and 6 months
|
To assess the anti-lymphoma efficacy of the combination of MGd and 90Yttrium-Zevalin therapy.
Disease response to treatment was categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or complete response/unconfirmed (CRu).
The overall response rate (ORR) was then calculated.
The time to treatment failure (TTF), overall survival (OS), and duration of response were determined.
|
At 1, 3 and 6 months
|
Study and Describe the Bio-locationization of Motexafin Gadolinium (MGd) in Tumors Using MRIs
Time Frame: At baseline (pre-treatment) and on Day 4 of treatment
|
To study the tumor-specific bio-localization of MGd in lymphoma through magnetic resonance imaging (MRI) in a subset of patients.
The first 2 patients of each cohort will have MRI imaging to measure if signal intensity, a correlate for MGd uptake, is increased in known areas of lymphomatous involvement.
|
At baseline (pre-treatment) and on Day 4 of treatment
|
Correlative Laboratory Studies
Time Frame: On Day 1 and 4
|
To explore correlative laboratory studies of MGd (ie, uptake of MGd by peripheral mononuclear cells, effect of MGd upon peripheral lymphocyte subset populations).
|
On Day 1 and 4
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew M. Evens, DO, MS, Northwestern University
- Principal Investigator: Leo I. Gordon, MD, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Photosensitizing Agents
- Dermatologic Agents
- Rituximab
- Motexafin gadolinium
Other Study ID Numbers
- NU 02H8
- 1346001 (Other Identifier: Northwestern University IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma (NHL)
-
Sun Yat-sen UniversityRecruitingRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)China
-
Gilead SciencesCompleted
-
Shanghai Miracogen Inc.RecruitingRelapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)China
-
Cullinan Oncology Inc.RecruitingA Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)NHL | NHL, Relapsed, AdultUnited States
-
University of PennsylvaniaCompletedNon-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell LymphomasUnited States
-
German High-Grade Non-Hodgkin's Lymphoma Study...Deutsche Krebshilfe e.V., Bonn (Germany)CompletedNon-Hodgkin's Lymphoma (NHL)Germany
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang University; The First Affiliated Hospital... and other collaboratorsSuspendedAcute Lymphoblastic Leukemia (ALL) | Non Hodgkin Lymphoma (NHL)China
-
Mundipharma Research LimitedTerminatedIndolent B-cell NHLAustralia, Slovakia
-
Czech Lymphoma Study GroupRecruitingNon Hodgkin Lymphoma (NHL)Czechia
-
Gilead SciencesWithdrawnDiffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHLUnited States
Clinical Trials on Rituxan
-
University of VermontGenentech, Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...Completed
-
Georgetown UniversityHackensack Meridian HealthActive, not recruitingChronic Lymphocytic LeukemiaUnited States
-
Hangzhou DAC Biotechnology Co., Ltd.Not yet recruitingAdvanced Solid Tumors | Hematological Malignancies
-
German Parkinson Study Group (GPS)Philipps University Marburg Medical Center; MSE Pharmazeutika GmbH, Louisenstr... and other collaboratorsCompletedProgressive Supranuclear PalsyGermany
-
Massachusetts General HospitalGenentech, Inc.WithdrawnKidney Insufficiency | Chronic Rejection
-
Massachusetts General HospitalGenentech, Inc.; BiogenWithdrawn
-
Genentech, Inc.CompletedMicroscopic Polyangiitis | Granulomatosis With PolyangiitisUnited States
-
Johns Hopkins UniversityCompletedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Massachusetts General HospitalGenentech, Inc.CompletedSialadenitis | Retroperitoneal Fibrosis | Autoimmune Pancreatitis | Pseudotumor